Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration for its Abbreviated New Drug Application, Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca® Tablets, 50 mg/25 mg of ViiV Healthcare Company. Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca®) had estimated annual sales of USD 666 million in the U.S.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,835 INR | -0.50% | +1.01% | +38.71% |
Jul. 16 | Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences | MT |
Jul. 15 | Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.71% | 10.06B | |
+55.35% | 815B | |
+31.64% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+15.51% | 247B | |
+16.72% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets